1
|
Nogueira de Brito R, Tanner S, Runk JV, Hoyos J. Looking through the lens of social science approaches: A scoping review of leishmaniases and Chagas disease research. Acta Trop 2024; 249:107059. [PMID: 37918504 DOI: 10.1016/j.actatropica.2023.107059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/27/2023] [Accepted: 10/30/2023] [Indexed: 11/04/2023]
Abstract
Scholars have called for increased attention to sociocultural, economic, historical, and political processes shaping Neglected Tropical Diseases (NTDs) ecology. We conducted a scoping review to identify major research themes and the knowledge gaps in social science literature in leishmaniases or Chagas disease (CD). Following the scoping review protocol, we first determined the focus of the review to be centered on identifying research that approaches leishmaniases and CD from social science perspective and was indexed by large, biomedically focused databases. We then searched PubMed and Web of Science using "Leishmaniasis" and "Chagas disease" with "social science" or "anthropology" as search terms. We analyzed 199 articles (123 on leishmaniases and 76 on CD), categorizing them into three main research themes. Sociocultural dimensions of the diseases (leishmaniases=60.2 %; CD=68.4 %) primarily focused on individuals' knowledge, practices, and behaviors, barriers to accessing healthcare (especially in endemic regions), psychosocial effects, stigma, and traditional treatments. Research focused on socioeconomic dimensions of the diseases (leishmaniases=29.3 %; CD=19.7 %) included topics like household characteristics, social capital, and infrastructure access. A final theme, the historical and political contexts of the diseases (Leishmaniases=10.5 %; CD=11.9 %) was less common than other themes. Here, studies consider civil war and the (re)emergence of leishmaniasis, as well as the significance of CD discovery for scientific and public health in Brazil, which is the most common country for research on both leishmaniases and CD that draws on social science approaches. Future directions for research include focusing on how social institutions and economic factors shape diseases education, control measures, healthcare access, and quality of life of people affected by NTDs. Greater attention to social sciences can help mitigate and undo the ways that structural biases have infiltrated biomedicine.
Collapse
Affiliation(s)
- Raíssa Nogueira de Brito
- Department of Anthropology, University of Georgia, Athens, GA 30602, United States; Center for the Ecology of Infectious Diseases, University of Georgia, Athens, GA 30602, United States.
| | - Susan Tanner
- Department of Anthropology, University of Georgia, Athens, GA 30602, United States
| | - Julie Velásquez Runk
- Environment and Sustainability Studies Program, Wake Forest University, Winston Salem, NC 27109, United States; Smithsonian Tropical Research Institute, Balboa, Ciudad de Panamá 0843-03092, Republic of Panama
| | - Juliana Hoyos
- Odum School of Ecology, University of Georgia, Athens, GA 30602, United States
| |
Collapse
|
2
|
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. PLoS Negl Trop Dis 2022; 16:e0010471. [PMID: 35696433 PMCID: PMC9232160 DOI: 10.1371/journal.pntd.0010471] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Revised: 06/24/2022] [Accepted: 05/05/2022] [Indexed: 11/19/2022] Open
Abstract
Background
A pressing need exists to develop vaccines for neglected diseases, including leishmaniasis. However, the development of new vaccines is dependent on their value to two key players–vaccine developers and manufacturers who need to have confidence in the global demand in order to commit to research and production; and governments (or other international funders) who need to signal demand based on the potential public health benefits of the vaccine in their local context, as well as its affordability. A detailed global epidemiological analysis is rarely available before a vaccine enters a market due to lack of resources as well as insufficient global data necessary for such an analysis. Our study seeks to bridge this information gap by providing a generalisable approach to estimating the commercial and public health value of a vaccine in development relying primarily on publicly available Global Burden of Disease (GBD) data. This simplified approach is easily replicable and can be used to guide discussions and investments into vaccines and other health technologies where evidence constraints exist. The approach is demonstrated through the estimation of the demand curve for a future leishmaniasis vaccine.
Methodology/Principal findings
We project the ability to pay over the period 2030–2040 for a vaccine preventing cutaneous and visceral leishmaniasis (CL / VL), using an illustrative set of countries which account for most of the global disease burden. First, based on previous work on vaccine demand projections in these countries and CL / VL GBD-reported incidence rates, we project the potential long-term impact of the vaccine on disability-adjusted life years (DALYs) averted as a result of reduced incidence. Then, we apply an economic framework to our estimates to determine vaccine affordability based on the abilities to pay of governments and global funders, leading to estimates of the demand and market size. Based on our estimates, the maximum ability-to-pay of a leishmaniasis vaccine (per course, including delivery costs), given the current estimates of incidence and population at risk, is higher than $5 for 25–30% of the countries considered, with the average value-based maximum price, weighted by quantity demanded, being $5.7–6 [$0.3 - $34.5], and total demand of over 560 million courses.
Conclusion/Significance
Our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay could make a vaccine for leishmaniasis commercially attractive to potential manufacturers. The methodology used can be equally applied to other technology developments targeting health in developing countries.
Collapse
|
3
|
Grifferty G, Shirley H, McGloin J, Kahn J, Orriols A, Wamai R. Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review. Res Rep Trop Med 2021; 12:135-151. [PMID: 34188584 PMCID: PMC8236266 DOI: 10.2147/rrtm.s278138] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Accepted: 05/06/2021] [Indexed: 11/23/2022] Open
Abstract
The leishmaniases are a group of four vector-borne neglected tropical diseases (NTDs) with 1.6 billion people in some 100 countries at risk. They occur in certain eco-epidemiological foci that reflect manipulation by human activities, such as migration, urbanization and deforestation, of which poverty, conflict and climate change are key drivers. Given their synergistic impacts, risk factors and the vulnerabilities of poor populations and the launch of a new 2030 roadmap for NTDs in the context of the global sustainability agenda, it is warranted to update the state of knowledge of the leishmaniases and their effects. Using existing literature, we review socioeconomic and psychosocial impacts of leishmaniasis within a framework of risk factors and vulnerabilities to help inform policy interventions. Studies show that poverty is an overarching primary risk factor. Low-income status fosters inadequate housing, malnutrition and lack of sanitation, which create and exacerbate complexities in access to care and treatment outcomes as well as education and awareness. The co-occurrence of the leishmaniases with malnutrition and HIV infection further complicate diagnosis and treatment, leading to poor diagnostic outcomes and therapeutic response. Even with free treatment, households may suffer catastrophic health expenditure from direct and indirect medical costs, which compounds existing financial strain in low-income communities for households and healthcare systems. The dermatological presentations of the leishmaniases may result in long-term severe disfigurement, leading to stigmatization, reduced quality of life, discrimination and mental health issues. A substantial amount of recent literature points to the vulnerability pathways and burden of leishmaniasis on women, in particular, who disproportionately suffer from these impacts. These emerging foci demonstrate a need for continued international efforts to address key risk factors and population vulnerabilities if leishmaniasis control, and ultimately elimination, is to be achieved by 2030.
Collapse
Affiliation(s)
- Grace Grifferty
- Department of Biology, Northeastern University, College of Science, Boston, MA, USA
| | - Hugh Shirley
- Department of Biochemistry, Northeastern University, College of Science, Boston, MA, USA.,Program in Medical Education, Harvard Medical School, Boston, MA, USA
| | - Jamie McGloin
- Department of Health Sciences, Northeastern University, Bouvé College of Health Sciences, Boston, MA, USA
| | - Jorja Kahn
- Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA
| | - Adrienne Orriols
- Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA
| | - Richard Wamai
- Department of Cultures, Societies and Global Studies, Northeastern University, College of Social Sciences and Humanities, Integrated Initiative for Global Health, Boston, MA, USA
| |
Collapse
|
4
|
Dubey P, Das A, Priyamvada K, Bindroo J, Mahapatra T, Mishra PK, Kumar A, Franco AO, Rooj B, Sinha B, Pradhan S, Banerjee I, Kumar M, Bano N, Kumar C, Prasad C, Chakraborty P, Kumar R, Kumar N, Kumar A, Singh AK, Kundan K, Babu S, Shah H, Karthick M, Roy N, Gill NK, Dwivedi S, Chaudhuri I, Hightower AW, Chapman LAC, Singh C, Sharma MP, Dhingra N, Bern C, Srikantiah S. Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India. Front Cell Infect Microbiol 2021; 11:648903. [PMID: 33842396 PMCID: PMC8024686 DOI: 10.3389/fcimb.2021.648903] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Accepted: 03/01/2021] [Indexed: 11/13/2022] Open
Abstract
As India moves toward the elimination of visceral leishmaniasis (VL) as a public health problem, comprehensive timely case detection has become increasingly important, in order to reduce the period of infectivity and control outbreaks. During the 2000s, localized research studies suggested that a large percentage of VL cases were never reported in government data. However, assessments conducted from 2013 to 2015 indicated that 85% or more of confirmed cases were eventually captured and reported in surveillance data, albeit with significant delays before diagnosis. Based on methods developed during these assessments, the CARE India team evolved new strategies for active case detection (ACD), applicable at large scale while being sufficiently effective in reducing time to diagnosis. Active case searches are triggered by the report of a confirmed VL case, and comprise two major search mechanisms: 1) case identification based on the index case's knowledge of other known VL cases and searches in nearby houses (snowballing); and 2) sustained contact over time with a range of private providers, both formal and informal. Simultaneously, house-to-house searches were conducted in 142 villages of 47 blocks during this period. We analyzed data from 5030 VL patients reported in Bihar from January 2018 through July 2019. Of these 3033 were detected passively and 1997 via ACD (15 (0.8%) via house-to-house and 1982 (99.2%) by light touch ACD methods). We constructed multinomial logistic regression models comparing time intervals to diagnosis (30-59, 60-89 and ≥90 days with <30 days as the referent). ACD and younger age were associated with shorter time to diagnosis, while male sex and HIV infection were associated with longer illness durations. The advantage of ACD over PCD was more marked for longer illness durations: the adjusted odds ratios for having illness durations of 30-59, 60-89 and >=90 days compared to the referent of <30 days for ACD vs PCD were 0.88, 0.56 and 0.42 respectively. These ACD strategies not only reduce time to diagnosis, and thus risk of transmission, but also ensure that there is a double check on the proportion of cases actually getting captured. Such a process can supplement passive case detection efforts that must go on, possibly perpetually, even after elimination as a public health problem is achieved.
Collapse
Affiliation(s)
- Pushkar Dubey
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Aritra Das
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Khushbu Priyamvada
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Joy Bindroo
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Tanmay Mahapatra
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Prabhas Kumar Mishra
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Ankur Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Ana O. Franco
- Institute for Global Health Sciences, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
| | - Basab Rooj
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Bikas Sinha
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Sreya Pradhan
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Indranath Banerjee
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Manash Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Nasreen Bano
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Chandan Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Chandan Prasad
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Parna Chakraborty
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Rakesh Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Niraj Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Aditya Kumar
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Abhishek Kumar Singh
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Kumar Kundan
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Sunil Babu
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Hemant Shah
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Morchan Karthick
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Nupur Roy
- National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare, Government of India, Delhi, India
| | - Naresh Kumar Gill
- National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare, Government of India, Delhi, India
| | - Shweta Dwivedi
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | - Indrajit Chaudhuri
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| | | | - Lloyd A C. Chapman
- Department of Medicine, University of California, San Francisco, San Francisco, CA, United States
- Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Chandramani Singh
- Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, India
| | | | - Neeraj Dhingra
- National Vector Borne Disease Control Programme, Ministry of Health and Family Welfare, Government of India, Delhi, India
| | - Caryn Bern
- Institute for Global Health Sciences, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
| | - Sridhar Srikantiah
- Bihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India
| |
Collapse
|
5
|
"Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia. PLoS Negl Trop Dis 2019; 13:e0007788. [PMID: 31693661 PMCID: PMC6834242 DOI: 10.1371/journal.pntd.0007788] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Accepted: 09/16/2019] [Indexed: 12/03/2022] Open
Abstract
Introduction Cutaneous leishmaniasis (CL), endemic in Bolivia, mostly affects poor people in rainforest areas. The current first-line treatment consists of systemic pentavalent antimonials (SPA) for 20 days and is paid for by the Ministry of Health (MoH). Long periods of drug shortages and a lack of safe conditions to deliver treatment are challenges to implementation. Intralesional pentavalent antimonials (ILPA) are an alternative to SPA. This study aims to compare the cost of ILPA and SPA, and to estimate the health and economic impacts of changing the first-line treatment for CL in a Bolivian endemic area. Methods The cost-per-patient treated was estimated for SPA and ILPA from the perspectives of the MoH and society. The quantity and unit costs of medications, staff time, transportation and loss of production were obtained through a health facility survey (N = 12), official documents and key informants. A one-way sensitivity analysis was conducted on key parameters to evaluate the robustness of the results. The annual number of patients treated and the budget impact of switching to ILPA as the first-line treatment were estimated under different scenarios of increasing treatment utilization. Costs were reported in 2017 international dollars (1 INT$ = 3.10 BOB). Results Treating CL using ILPA was associated with a cost-saving of $248 per-patient-treated from the MoH perspective, and $688 per-patient-treated from the societal perspective. Switching first-line treatment to ILPA while maintaining the current budget would allow two-and-a-half times the current number of patients to be treated. ILPA remained cost-saving compared to SPA in the sensitivity analysis. Conclusions The results of this study support a shift to ILPA as the first-line treatment for CL in Bolivia and possibly in other South American countries. Cutaneous leishmaniasis is a neglected tropical disease which causes chronic skin ulcers and disproportionally affects the poorest of the poor. The current first-line treatment, based on systemic pentavalent antimonials, is quite toxic for patients but also expensive for governments and patients. Given limited budgets, national decision-makers need to know not only the efficacy of alternative treatments, but also how to maximise the population health impact of available resources. To strengthen the evidence base for the scale-up of effective NTD interventions in the era of universal health coverage, we conducted cost-effectiveness analyses and estimations of population-level impact of the implementation of intralesional pentavalent antimonials as first-line treatment for cutaneous leishmaniasis using realistic scenarios. Our results demonstrate that changing first-line treatment would have considerable economic advantages for patients due to the shorter treatment duration (savings in terms of food, accommodation, transport, productivity loss); and for the national control program due to the reduced use of drugs and staff time. In addition, this change would offer better value for money given that two-and-a-half times the current number of patients could be treated with the current expenditure level if intralesional pentavalent antimonials were offered to eligible patients.
Collapse
|
6
|
Jayakumar B, Murthy N, Misra K, Burza S. "It's just a fever": Gender based barriers to care-seeking for visceral leishmaniasis in highly endemic districts of India: A qualitative study. PLoS Negl Trop Dis 2019; 13:e0007457. [PMID: 31247011 PMCID: PMC6597040 DOI: 10.1371/journal.pntd.0007457] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 05/10/2019] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION Diagnosis and treatment for visceral leishmaniasis (VL) is considered to be delayed amongst poor, rural women in highly endemic districts of Bihar and Jharkhand. The objective of this study was to assess and understand barriers to VL diagnosis and treatment for women in endemic districts with a high burden of VL. METHODS The study used a stratified and purposive sample of 33 female patients with VL, 11 health staff, 11 local (unqualified) health providers and 12 groups of community elders drawn from ten districts in Bihar and four in Jharkhand with high burdens of VL. The study was conducted within an exploratory and inductive framework, using semi-structured in-depth interviews and discussions. RESULTS Women accessing treatment more quickly tended to move faster from treating their symptoms on their own to seeking care from local providers. Perception among female patients of the illness being not serious (owing to initially non-specific and mild symptoms), lack of money, prioritisation of household chores over their need to seek care and the absence of a male guardian to accompany them in seeking care at facilities worked together to drive these choices. Most patients and their families did not suspect VL as the cause for their non-specific symptoms, but when VL was suspected, treatment shopping ended. Lack of prioritization of women's health issues appears to be a pervasive underlying factor. Public health facilities were not an early treatment choice for the majority, but where it was, the diagnosis of VL was often not considered when presenting with under 2 weeks of symptoms, nor were appropriate follow-up plans instituted. CONCLUSION The insidious presentation of VL and the low prioritisation of women's health need to be jointly addressed through messages that emphasise the importance of early diagnosis and treatment of disease, which is low-cost in time and money when managed in public health facilities. Clear messages that project prioritising women's care-seeking over household work as a smart choice and the need for rallying male support are needed. Additionally, efforts to reduce missed opportunities through early case suspicion and engaging private providers to better counsel women with suspected VL could close critical gaps in the continuum of care.
Collapse
Affiliation(s)
| | - Nirmala Murthy
- Foundation for Research in Health Systems, Bangalore, India
| | | | | |
Collapse
|
7
|
Sunyoto T, Boelaert M, Meheus F. Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review. Expert Rev Anti Infect Ther 2019; 17:57-69. [PMID: 30513027 DOI: 10.1080/14787210.2019.1555471] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 11/30/2018] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Leishmaniasis is a poverty-related disease that causes a significant socioeconomic burden to affected households. Visceral leishmaniasis is fatal if untreated, yet illness costs may lead to delays in accessing care. Skin manifestations of leishmaniasis cause a psychological burden and even longer treatment trajectories. The objective of this review is to evaluate illness costs associated with leishmaniasis across different settings (Asia, Africa, and Latin America) and the consequences to households. Areas covered: Through a systematic review of cost-of-illness studies, we documented the distribution of costs, the health-seeking behavior, and the consequences of leishmaniasis. We discuss the value of cost-of-illness studies for leishmaniasis. Expert commentary: Despite the free provision of diagnostics and treatment in the public health care sector, out-of-pocket payments remain substantial. There has been progress in addressing the economic burden of leishmaniasis, particularly through the elimination initiative in the Indian subcontinent. Though the illness cost is decreasing due to shorter treatment regimens and better access to care, the situation remains challenging in Africa. Improvement of control tools is critical. There is a need to update cost estimates to inform policy-making and ensure sustainable solutions to reduce financial barriers to leishmaniasis care, especially in pursuing universal health coverage.
Collapse
Affiliation(s)
- Temmy Sunyoto
- a Public Health Department , Institute of Tropical Medicine , Antwerpen , Belgium
| | - Marleen Boelaert
- a Public Health Department , Institute of Tropical Medicine , Antwerpen , Belgium
| | - Filip Meheus
- b Early Detection and Prevention Section , International Agency for Research on Cancer , Lyon , France
| |
Collapse
|
8
|
Sunyoto T, Adam GK, Atia AM, Hamid Y, Babiker RA, Abdelrahman N, Vander Kelen C, Ritmeijer K, Alcoba G, den Boer M, Picado A, Boelaert M. " Kala-Azar is a Dishonest Disease": Community Perspectives on Access Barriers to Visceral Leishmaniasis (Kala-Azar) Diagnosis and Care in Southern Gadarif, Sudan. Am J Trop Med Hyg 2018; 98:1091-1101. [PMID: 29488462 PMCID: PMC5928836 DOI: 10.4269/ajtmh.17-0872] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Early diagnosis and treatment is the principal strategy to control visceral leishmaniasis (VL), or kala-azar in East Africa. As VL strikes remote rural, sparsely populated areas, kala-azar care might not be accessed optimally or timely. We conducted a qualitative study to explore access barriers in a longstanding kala-azar endemic area in southern Gadarif, Sudan. Former kala-azar patients or caretakers, community leaders, and health-care providers were purposively sampled and thematic data analysis was used. Our study participants revealed the multitude of difficulties faced when seeking care. The disease is well known in the area, yet misconceptions about causes and transmission persist. The care-seeking itineraries were not always straightforward: “shopping around” for treatments are common, partly linked to difficulties in diagnosing kala-azar. Kala-azar is perceived to be “hiding,” requiring multiple tests and other diseases must be treated first. Negative perceptions on quality of care in the public hospitals prevail, with the unavailability of drugs or staff as the main concern. Delay to seek care remains predominantly linked to economic constraint: albeit treatment is for free, patients have to pay out of pocket for everything else, pushing families further into poverty. Despite increased efforts to tackle the disease over the years, access to quality kala-azar care in this rural Sudanese context remains problematic. The barriers explored in this study are a compelling reminder of the need to boost efforts to address these barriers.
Collapse
Affiliation(s)
- Temmy Sunyoto
- Institute of Tropical Medicine, Antwerp, Belgium.,Médecins Sans Frontières Campaign for Access to Medicines, Geneva, Switzerland
| | - Gamal K Adam
- Faculty of Medicine, Kala-Azar Research Center, University of Gadarif, Al Qadarif, Sudan
| | - Atia M Atia
- Faculty of Medicine, Kala-Azar Research Center, University of Gadarif, Al Qadarif, Sudan
| | - Yassin Hamid
- Faculty of Medicine, Kala-Azar Research Center, University of Gadarif, Al Qadarif, Sudan
| | - Rabie Ali Babiker
- Faculty of Medicine, Kala-Azar Research Center, University of Gadarif, Al Qadarif, Sudan
| | - Nugdalla Abdelrahman
- Faculty of Medicine, Kala-Azar Research Center, University of Gadarif, Al Qadarif, Sudan
| | | | | | | | - Margriet den Boer
- KalaCORE Consortium, London, United Kingdom.,Médecins Sans Frontières, Amsterdam, The Netherlands
| | - Albert Picado
- ISGlobal, Barcelona Institute of Global Health, Barcelona, Spain
| | | |
Collapse
|
9
|
DebRoy S, Prosper O, Mishoe A, Mubayi A. Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings. Emerg Themes Epidemiol 2017; 14:10. [PMID: 28936226 PMCID: PMC5604165 DOI: 10.1186/s12982-017-0065-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 08/30/2017] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES Neglected tropical diseases (NTD), account for a large proportion of the global disease burden, and their control faces several challenges including diminishing human and financial resources for those distressed from such diseases. Visceral leishmaniasis (VL), the second-largest parasitic killer (after malaria) and an NTD affects poor populations and causes considerable cost to the affected individuals. Mathematical models can serve as a critical and cost-effective tool for understanding VL dynamics, however, complex array of socio-economic factors affecting its dynamics need to be identified and appropriately incorporated within a dynamical modeling framework. This study reviews literature on vector-borne diseases and collects challenges and successes related to the modeling of transmission dynamics of VL. Possible ways of creating a comprehensive mathematical model is also discussed. METHODS Published literature in three categories are reviewed: (i) identifying non-traditional but critical mechanisms for VL transmission in resource limited regions, (ii) mathematical models used for dynamics of Leishmaniasis and other related vector borne infectious diseases and (iii) examples of modeling that have the potential to capture identified mechanisms of VL to study its dynamics. RESULTS This review suggests that VL elimination have not been achieved yet because existing transmission dynamics models for VL fails to capture relevant local socio-economic risk factors. This study identifies critical risk factors of VL and distribute them in six categories (atmosphere, access, availability, awareness, adherence, and accedence). The study also suggests novel quantitative models, parts of it are borrowed from other non-neglected diseases, for incorporating these factors and using them to understand VL dynamics and evaluating control programs for achieving VL elimination in a resource-limited environment. CONCLUSIONS Controlling VL is expensive for local communities in endemic countries where individuals remain in the vicious cycle of disease and poverty. Smarter public investment in control programs would not only decrease the VL disease burden but will also help to alleviate poverty. However, dynamical models are necessary to evaluate intervention strategies to formulate a cost-effective optimal policy for eradication of VL.
Collapse
Affiliation(s)
- Swati DebRoy
- Department of Mathematics and Computational Science, University of South Carolina, Beaufort, SC USA
| | - Olivia Prosper
- Department of Mathematics, University of Kentucky, Lexington, KY USA
| | - Austin Mishoe
- Department of Mathematics and Computational Science, University of South Carolina, Beaufort, SC USA
| | - Anuj Mubayi
- Simon A. Levin-Mathematical Computational and Modeling Science Center, School of Human Evolution and Social Change, Arizona State University, Tempe, AZ USA
| |
Collapse
|
10
|
Worldwide risk factors in leishmaniasis. ASIAN PAC J TROP MED 2016; 9:925-932. [PMID: 27794384 DOI: 10.1016/j.apjtm.2016.06.021] [Citation(s) in RCA: 138] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2016] [Revised: 06/01/2016] [Accepted: 06/10/2016] [Indexed: 11/22/2022] Open
Abstract
Recently, vector-borne parasitic diseases such as leishmaniasis have been emerged or re-emerged in many geographical areas and resulted in global health and economic concerns that involve humans, domestic animals and wild life. The ecology and epidemiology of leishmaniasis are affected by the between host, reservoir and vector (human, animal and sandfly) and the environment. Important drivers for the emergence and spread of leishmaniasis include environmental factors such as alterations in temperature and water storage, irrigation habits, deforestation, climate changes, immunosuppression by HIV or organ transplant, development of drug resistance, increase traveling to endemic regions and dog importation. War, poor socio-economic status and low level household are also major contributors to the spread of this disease. Health education via the public media and training should be implemented by international organizations and governmental agencies in collaboration with research institutions. Fully protection during transmission season, using bednets and insecticides and reservoirs' control should be also mentioned in the planning. Based on the findings of the recent studies and high prevalence of leishmaniasis, it is concluded that serious public health monitoring should be considered.
Collapse
|
11
|
Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg 2016; 94:489-93. [PMID: 26787156 DOI: 10.4269/ajtmh.15-0408] [Citation(s) in RCA: 157] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 11/17/2015] [Indexed: 11/07/2022] Open
Abstract
Leishmaniasis continues to pose a major public health problem worldwide. With new epidemics occurring in endemic areas and the spread of the disease to previously free areas because of migration, tourism, and military activities, there is a great need for the development of an effective vaccine. Leishmaniasis is a disease of the poor, occurring mostly in remote rural villages with poor housing and little or no access to modern health-care facilities. In endemic areas, diagnosis of any form of leishmaniasis puts a huge financial strain on an already meagre financial resource at both the individual and community levels. Most often families need to sell their assets (land and livestock) or take loans from informal financial outfits with heavy interest rates to pay for the diagnosis and treatment of leishmaniasis. Here, we discuss the disease with special emphasis on its socioeconomic impact on the affected individual and community. In addition, we highlight the reasons why continued research aimed at developing an effective Leishmania vaccine is necessary.
Collapse
Affiliation(s)
- Ifeoma Okwor
- Department of Medical Microbiology, Faculty of Health Sciences, University of Manitoba, Manitoba, Canada; Department of Immunology, Faculty of Health Sciences, University of Manitoba, Manitoba, Canada
| | - Jude Uzonna
- Department of Medical Microbiology, Faculty of Health Sciences, University of Manitoba, Manitoba, Canada; Department of Immunology, Faculty of Health Sciences, University of Manitoba, Manitoba, Canada
| |
Collapse
|
12
|
Rock KS, le Rutte EA, de Vlas SJ, Adams ER, Medley GF, Hollingsworth TD. Uniting mathematics and biology for control of visceral leishmaniasis. Trends Parasitol 2015; 31:251-9. [PMID: 25913079 DOI: 10.1016/j.pt.2015.03.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 03/11/2015] [Accepted: 03/18/2015] [Indexed: 11/26/2022]
Abstract
The neglected tropical disease (NTD) visceral leishmaniasis (VL) has been targeted by the WHO for elimination as a public health problem on the Indian subcontinent by 2017 or earlier. To date there is a surprising scarcity of mathematical models capable of capturing VL disease dynamics, which are widely considered central to planning and assessing the efficacy of interventions. The few models that have been developed are examined, highlighting the necessity for better data to parameterise and fit these and future models. In particular, the characterisation and infectiousness of the different disease stages will be crucial to elimination. Modelling can then assist in establishing whether, when, and how the WHO VL elimination targets can be met.
Collapse
Affiliation(s)
- Kat S Rock
- Warwick Mathematics Institute, University of Warwick, Coventry CV4 7AL, UK; Warwick Infectious Disease Epidemiology Research (WIDER), University of Warwick, Coventry CV4 7AL, UK; School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.
| | - Epke A le Rutte
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
| | - Sake J de Vlas
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
| | - Emily R Adams
- Warwick Infectious Disease Epidemiology Research (WIDER), University of Warwick, Coventry CV4 7AL, UK; Parasitology Department, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
| | - Graham F Medley
- Social and Mathematical Epidemiology Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - T Deirdre Hollingsworth
- Warwick Mathematics Institute, University of Warwick, Coventry CV4 7AL, UK; Warwick Infectious Disease Epidemiology Research (WIDER), University of Warwick, Coventry CV4 7AL, UK; School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
| |
Collapse
|
13
|
Boettcher JP, Siwakoti Y, Milojkovic A, Siddiqui NA, Gurung CK, Rijal S, Das P, Kroeger A, Banjara MR. Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India. BMC Infect Dis 2015; 15:43. [PMID: 25656298 PMCID: PMC4335691 DOI: 10.1186/s12879-015-0767-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 01/15/2015] [Indexed: 11/10/2022] Open
Abstract
Background To eliminate visceral leishmaniasis (VL) in India and Nepal, challenges of VL diagnosis, treatment and reporting need to be identified. Recent data indicate that VL is underreported and patients face delays when seeking treatment. Moreover, VL surveillance data might not reach health authorities on time. This study quantifies delays for VL diagnosis and treatment, and analyses the duration of VL reporting from district to central health authorities in India and Nepal. Methods A cross-sectional study conducted in 12 districts of Terai region, Nepal, and 9 districts of Bihar State, India, in 2012. Patients were interviewed in hospitals or at home using a structured questionnaire, health managers were interviewed at their work place using a semi-structured questionnaire and in-depth interviews were conducted with central level health managers. Reporting formats were evaluated. Data was analyzed using two-tailed Mann-Whitney U or Fisher’s exact test. Results 92 VL patients having experienced 103 VL episodes and 49 district health managers were interviewed. Patients waited in Nepal 30 days (CI 18-42) before seeking health care, 3.75 times longer than in Bihar (8d; CI 4-12). Conversely, the lag time from seeking health care to receiving a VL diagnosis was 3.6x longer in Bihar (90d; CI 68-113) compared to Nepal (25d; CI 13-38). The time span between diagnosis and treatment was short in both countries. VL reporting time was in Nepal 19 days for sentinel sites and 76 days for “District Public Health Offices (DPHOs)”. In Bihar it was 28 days for “District Malaria Offices”. In Nepal, 73% of health managers entered data into computers compared to 16% in Bihar. In both countries reporting was mainly paper based and standardized formats were rarely used. Conclusions To decrease the delay between onset of symptoms and getting a proper diagnosis and treatment the approaches in the two countries vary: In Nepal health education for seeking early treatment are needed while in Bihar the use of private and non-formal practitioners has to be discouraged. Reinforcement of VL sentinel reporting in Bihar, reorganization of DPHOs in Nepal, introduction of standardized reporting formats and electronic reporting should be conducted in both countries. Electronic supplementary material The online version of this article (doi:10.1186/s12879-015-0767-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jan P Boettcher
- Centre for Biological Threats and Special Pathogens, Robert Koch-Institute, Nordufer 20, Berlin, 13353, Germany.
| | - Yubaraj Siwakoti
- Valley College of Technical Sciences, Purbanchal University, Maharajgunj, Kathmandu, 44600, Nepal.
| | - Ana Milojkovic
- Clinical and Molecular Oncology, Max Delbrück Centrum für Molekulare Medizin, Berlin-Buch, Germany.
| | - Niyamat A Siddiqui
- Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India.
| | - Chitra K Gurung
- Public Health and Infectious Disease Research Center, New Baneshwor, Kathmandu, Nepal.
| | - Suman Rijal
- BP Koirala Institute of Health Sciences, Dharan, Nepal.
| | - Pradeep Das
- Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India.
| | - Axel Kroeger
- Special Programme for Research and Training in Tropical Diseases WHO-TDR, Geneva, Switzerland. .,Freiburg University Medical Centre, Zentrum für Medizin und Gesundheit, Freiburg, Germany.
| | - Megha R Banjara
- Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
| |
Collapse
|
14
|
Kauhl B, Pilot E, Rao R, Gruebner O, Schweikart J, Krafft T. Estimating the spatial distribution of acute undifferentiated fever (AUF) and associated risk factors using emergency call data in India. A symptom-based approach for public health surveillance. Health Place 2014; 31:111-9. [PMID: 25463924 DOI: 10.1016/j.healthplace.2014.11.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 09/22/2014] [Accepted: 11/02/2014] [Indexed: 10/24/2022]
Abstract
The System for Early-warning based on Emergency Data (SEED) is a pilot project to evaluate the use of emergency call data with the main complaint acute undifferentiated fever (AUF) for syndromic surveillance in India. While spatio-temporal methods provide signals to detect potential disease outbreaks, additional information about socio-ecological exposure factors and the main population at risk is necessary for evidence-based public health interventions and future preparedness strategies. The goal of this study is to investigate whether a spatial epidemiological analysis at the ecological level provides information on urban-rural inequalities, socio-ecological exposure factors and the main population at risk for AUF. Our results displayed higher risks in rural areas with strong local variation. Household industries and proximity to forests were the main socio-ecological exposure factors and scheduled tribes were the main population at risk for AUF. These results provide additional information for syndromic surveillance and could be used for evidence-based public health interventions and future preparedness strategies.
Collapse
Affiliation(s)
- Boris Kauhl
- Department of International Health, CAPHRI School of Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences. Maastricht University, The Netherlands.
| | - Eva Pilot
- Department of Health, Ethics & Society, CAPHRI School of Public Health and Primary Care, Maastricht University, The Netherlands
| | - Ramana Rao
- GVK Emergency Management Reseach Institute, Hyderabad, Andhra Pradesh, India
| | - Oliver Gruebner
- Department of Epidemiology, Columbia University, NY, United States
| | - Jürgen Schweikart
- Beuth University of Applied Sciences, Department III, Civil Engineering and Geoinformatics, Berlin, Germany
| | - Thomas Krafft
- Department of International Health, CAPHRI School of Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences. Maastricht University, The Netherlands; Institute of Environment Education and Research, Bharati Vidyapeeth University, Pune, India
| |
Collapse
|
15
|
Malaviya P, Picado A, Hasker E, Ostyn B, Kansal S, Singh RP, Shankar R, Boelaert M, Sundar S. Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System. Int J Epidemiol 2014; 43:1450-7. [PMID: 25186307 DOI: 10.1093/ije/dyu178] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The Muzaffarpur-TMRC Health and Demographic Surveillance System (HDSS), established in 2007, was developed as an enlargement of the scope of a research collaboration on the project Visceral Leishmaniasis in Bihar, which had been ongoing since 2005. The HDSS is located in a visceral leishmaniasis (VL)-endemic area in the Muzaffarpur district of Bihar state in India. It is the only HDSS conducting research on VL, which is a vector-borne infectious disease transmitted by female phlebotomine sandflies and is fatal if left untreated. Currently the HDSS serves a population of over 105,000 in 66 villages. The HDSS collects data on vital events including pregnancies, births, deaths, migration and marriages, as well as other socio-economic indicators, at regular intervals. Incident VL cases are identified. The HDSS team is experienced in conducting both qualitative and quantitative studies, sample collection and rapid diagnostic tests in the field. In each village, volunteers connect the HDSS team with the community members. The Muzaffarpur-TMRC HDSS provides opportunities for studies on VL and other neglected tropical diseases (NTDs) and their interaction with demographic events such as migration. Queries related to research collaborations and data sharing can be sent to Dr Shyam Sundar at [drshyamsundar@hotmail.com].
Collapse
Affiliation(s)
- Paritosh Malaviya
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Albert Picado
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Epco Hasker
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Bart Ostyn
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Sangeeta Kansal
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Rudra Pratap Singh
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Ravi Shankar
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Marleen Boelaert
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Shyam Sundar
- Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, Institute of Tropical Medicine, Antwerp, Belgium and Barcelona Centre for International Health Research, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
16
|
Picado A, Ostyn B, Singh SP, Uranw S, Hasker E, Rijal S, Sundar S, Boelaert M, Chappuis F. Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal. PLoS One 2014; 9:e87641. [PMID: 24498159 PMCID: PMC3909193 DOI: 10.1371/journal.pone.0087641] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 12/30/2013] [Indexed: 11/22/2022] Open
Abstract
There is increasing interest in the role of asymptomatic infection in transmission of Visceral Leishmaniasis (VL). We studied the individual, household and environmental factors associated with asymptomatic Leishmania donovani infected individuals and VL. 7,538 individuals living in VL endemic villages in India and Nepal were divided into three mutually exclusive groups based on their VL history and Direct Agglutination Test (DAT) results in yearly serosurveys over a two-year period. The groups were (1) VL cases, (2) asymptomatically infected individuals (seroconverters) and (3) seronegative individuals. VL cases and seroconverters were compared to seronegative individuals in mixed logistic regression models. The risk of seroconversion and disease was significantly increased in individuals aged 14 to 24 years old and by the presence of other DAT-positive, asymptomatically infected individuals and VL cases in the house. The risk of seroconversion was higher in Indian than in Nepalese villages and it increased significantly with age, but not so for VL. This study demonstrates that, when risk factors for leishmanial infection and VL disease are evaluated in the same population, epidemiological determinants for asymptomatic infection and VL are largely similar.
Collapse
Affiliation(s)
- Albert Picado
- Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Barcelona, Spain
- * E-mail:
| | - Bart Ostyn
- Institute of Tropical Medicine, Antwerp, Belgium
| | | | | | - Epco Hasker
- Institute of Tropical Medicine, Antwerp, Belgium
| | - Suman Rijal
- BP Koirala Institute of Health Sciences, Dharan, Nepal
| | | | | | | |
Collapse
|
17
|
Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014; 8:e2603. [PMID: 24392168 PMCID: PMC3879255 DOI: 10.1371/journal.pntd.0002603] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2013] [Accepted: 11/07/2013] [Indexed: 01/23/2023] Open
Abstract
Background Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 mg/Kg intravenous liposomal amphotericin B (Ambisome) demonstrated a 98% cure rate at 6-months. Between July 2007 and August 2012, Médecins Sans Frontières (MSF) and the Rajendra Memorial Research Institute (RMRI) implemented a VL treatment project in Bihar, India—an area highly endemic for Leishmania donovani—using this regimen as first-line treatment. Methods and Principal Findings Intravenous Ambisome 20 mg/kg was administered in four doses of 5 mg/kg over 4–10 days, depending on the severity of disease. Initial clinical cure at discharge was defined as improved symptoms, cessation of fever, and recession of spleen enlargement. This observational retrospective cohort study describes 8749 patients with laboratory-confirmed primary VL treated over a 5-year period: 1396 at primary healthcare centers, 7189 at hospital, and 164 at treatment camps. Initial clinical cure was achieved in 99.3% of patients (8692/8749); 0.3% of patients (26/8749) defaulted from treatment and 0.4% (31/8749) died. Overall, 1.8% of patients (161/8749) were co-infected with HIV and 0.6% (51/8749) with tuberculosis. Treatment was discontinued because of severe allergic reactions in 0.1% of patients (7/8749). Overall, 27 patients (0.3%) were readmitted with post Kala-azar dermal leishmaniasis (PKDL). Risk factors for late presentation included female sex, age >15 years and being from a scheduled caste. In 2012, a long-term efficacy survey in the same area of Bihar determined relapse rates of VL after 5 years' intervention with Ambisome. Of 984 immunocompetent patients discharged between September 2010 and December 2011, 827 (84.0%) were traced in order to determine their long-term outcomes. Of these, 20 patients (2.4%) had relapsed or received further treatment for VL. Of those completing 6, 12, and 15 month follow-up, 0.3% (2/767), 3.7% (14/383), and 2.4% (4/164), respectively, had relapsed. The mean ±SD time-to-relapse was 9.6±3.0 months. Significance This is the largest cohort of VL patients treated with 20 mg/kg Ambisome worldwide. The drug has high initial and long-term efficacy, and a low rate of adverse reactions when administered under field conditions in Bihar, India. Although challenging, its use as first line treatment in rural settings in Bihar is safe and feasible. Visceral leishmaniasis (VL), also known as Kala-azar, is a protozoan parasitic disease transmitted by phlebotomine sandflies. After malaria, VL accounts for the second-highest burden of parasitic diseases worldwide. India has half of all the VL patients worldwide, of which up to 90% are in Bihar state. Between 2007–2012, Médecins Sans Frontières (MSF) together with the Rajendra Memorial Research Institute (RMRI) supported existing health structures in Vaishali district, Bihar, by treating 8749 VL patients with intravenous liposomal amphotericin B (Ambisome) 20 mg/kg. Initial cure rate was high, with low default and mortality rates. We describe the demographic and clinical characteristics of this large patient group, including risk factors for late presentation. Ambisome can be given in short courses and is safer, better tolerated, and more effective than existing VL treatments. The MSF-supported program treated nearly 1400 ambulatory patients in rural primary healthcare centers, using existing government facilities and non-incentivized staff, demonstrating that a resource-limited healthcare system in a rural setting can meet the cold chain and human resource standards required to administer Ambisome safely. We also describe a long-term follow-up survey showing a continuing low VL relapse rate after 5 years of routine use of Ambisome. More relapses occurred after 6-month follow-up; suggesting a 12-month follow-up in future VL studies may be more appropriate.
Collapse
|
18
|
Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balsegaram M, Das P. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis 2014; 8:e2536. [PMID: 24392166 PMCID: PMC3879206 DOI: 10.1371/journal.pntd.0002536] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2013] [Accepted: 09/30/2013] [Indexed: 12/13/2022] Open
Abstract
Background A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen. Methods and Principal Findings This is an observational retrospective cohort study of all VL patients treated by the MSF program from July 2007 to August 2012. Intravenous Ambisome was administered to 8749 patients with VL in four doses of 5 mg/kg (for a total dose of 20 mg/kg) over 4–10 days, depending on the severity of disease. Out of 8588 patients not known to be HIV-positive, 8537 (99.4%) were discharged as initial cures, 24 (0.3%) defaulted, and 27 (0.3%) died during or immediately after treatment. In total, 1.4% (n = 119) of the initial cured patients re-attended the programme with parasitologically confirmed VL relapse, with a median time to relapse of 10.1 months. Male sex, age <5 years and ≥45 years, a decrease in spleen size at time of discharge of ≤0.5 cm/day, and a shorter duration of symptoms prior to seeking treatment were significantly associated with relapse. Spleen size at admission, hemoglobin level, nutritional status, and previous history of relapse were not associated with relapse. Conclusions This is the largest cohort of VL patients treated with Ambisome worldwide. The risk factors for relapse included male sex, age <5 and ≥45 years, a smaller decrease in splenomegaly at discharge, and a shorter duration of symptoms prior to seeking treatment. The majority of relapses in this cohort occurred 6–12 months following treatment, suggesting that a 1-year follow-up is appropriate in future studies. Visceral leishmaniasis (VL), also known as Kala azar, accounts for the second-highest burden of parasitic disease worldwide. Fifty percent of VL cases worldwide occur in India, and up to 90% of these in the state of Bihar. Up to 10% of VL patients relapse within 6 months of treatment, particularly if co-infected with HIV. Limited data are available regarding relapse in patients with intact immune systems. Between 2007–2012, with support of the Rajendra Memorial Research Institute(RMRI), Médecins Sans Frontières (MSF) treated VL patients in Bihar with 20 mg/kg liposomal amphotericin B (Ambisome). Here we identify risk factors for relapse in immunocompetent patients by comparing the demographics and clinical characteristics of 119 patients testing negative for HIV who experienced parasitologically-confirmed VL relapse against those of the remaining 8418 patients not known to have relapsed. Male sex, age <5 years and ≥45 years, shorter duration of symptoms prior to seeking treatment, and a smaller reduction in spleen size by time of discharge were all risk factors for relapse. The majority of relapses occurred 6–12 months post-treatment with Ambisome. The conventional period of follow-up is 6 months. Considering the aim of elimination in the Indian subcontinent, this data suggests that 1-year follow-up is necessary.
Collapse
Affiliation(s)
- Sakib Burza
- Médecins Sans Frontières, New Delhi, India
- * E-mail:
| | - Prabhat K. Sinha
- Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India
| | | | | | | | - Neena Verma
- Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India
| | | | - Pradeep Das
- Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India
| |
Collapse
|
19
|
Abstract
Positive Health of the communities could only be brought out through the interrelationship between conventional health sector and other development sectors. It was a dream that came true when World Health Organization (WHO) accepted Primary Health Care (PHC) as the major tool to achieve its proposed goal of Health For All (HFA) by 2000 A.D., but we could not succeed as expected. Now we have the Millennium Development Goals (MDG), which place health at the heart of development but the achievements in health is still challenging. The literature search in this article has been conducted in Pub Med and Google scholar, with the aim to draw references to discuss the major health issues and ways to tackle them. The current article briefly narrates the burden and complexities of challenges faced by the present global health. Revisiting the concept of PHC and reaffirming our solidarity to this philosophy is the need of this hour.
Collapse
Affiliation(s)
- Ts Anish
- Department of Community Medicine, Government Medical College, Thiruvananthapuram, Kerala, India
| | | |
Collapse
|
20
|
Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S. Visceral leishmaniasis in rural bihar, India. Emerg Infect Dis 2013; 18:1662-4. [PMID: 23017164 PMCID: PMC3471608 DOI: 10.3201/eid1810.111083] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
To identify factors associated with incidence of visceral leishmaniasis (VL), we surveyed 13,416 households in Bihar State, India. VL was associated with socioeconomic status, type of housing, and belonging to the Musahar caste. Annual coverage of indoor residual insecticide spraying was 12%. Increasing such spraying can greatly contribute to VL control.
Collapse
Affiliation(s)
- Epco Hasker
- Institute of Tropical Medicine, Antwerp, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, Milani B, Gaspani S, Potet J, Chappuis F. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 2012; 17:493-510. [PMID: 23167833 PMCID: PMC3518293 DOI: 10.1517/14728214.2012.748036] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients' access to this life-saving drug remain. AREAS COVERED This article provides a review of clinical studies on LAMB for VL and other forms of leishmaniasis. The current development of generic versions of LAMB and related challenges are also discussed. EXPERT OPINION LAMB proved to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level. Despite requiring higher doses, LAMB is the drug of choice to treat vulnerable groups (e.g., pregnant or HIV positive) and relapsing VL patients in East Africa. LAMB should be included in national VL guidelines and registered in all VL endemic countries. Its cost should be further reduced and regulatory pathways to prove bioequivalence for generic LAMB products should be implemented.
Collapse
|